nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ADORA1—Pentoxifylline—systemic scleroderma	0.321	0.445	CbGbCtD
Mefloquine—ADORA2A—Pentoxifylline—systemic scleroderma	0.284	0.394	CbGbCtD
Mefloquine—ABCB1—Lisinopril—systemic scleroderma	0.0264	0.0367	CbGbCtD
Mefloquine—HBA2—dermis—systemic scleroderma	0.0253	0.294	CbGeAlD
Mefloquine—ABCB1—Captopril—systemic scleroderma	0.0198	0.0275	CbGbCtD
Mefloquine—CYP2D6—Captopril—systemic scleroderma	0.0186	0.0259	CbGbCtD
Mefloquine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0156	0.0216	CbGbCtD
Mefloquine—ABCB1—Prednisone—systemic scleroderma	0.0124	0.0173	CbGbCtD
Mefloquine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00933	0.013	CbGbCtD
Mefloquine—HBA2—artery—systemic scleroderma	0.00913	0.106	CbGeAlD
Mefloquine—HBA2—endothelium—systemic scleroderma	0.00771	0.0896	CbGeAlD
Mefloquine—CYP3A4—Prednisone—systemic scleroderma	0.00746	0.0104	CbGbCtD
Mefloquine—HBA2—blood vessel—systemic scleroderma	0.00711	0.0827	CbGeAlD
Mefloquine—ABCB1—Methotrexate—systemic scleroderma	0.00624	0.00867	CbGbCtD
Mefloquine—HBA1—connective tissue—systemic scleroderma	0.00397	0.0462	CbGeAlD
Mefloquine—HBA2—connective tissue—systemic scleroderma	0.00365	0.0424	CbGeAlD
Mefloquine—HBA1—skin of body—systemic scleroderma	0.00359	0.0417	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—systemic scleroderma	0.00334	0.0388	CbGeAlD
Mefloquine—HBA2—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.0033	0.165	CbGpPWpGaD
Mefloquine—HBA2—skin of body—systemic scleroderma	0.00329	0.0383	CbGeAlD
Mefloquine—HBA1—Effects of Nitric Oxide—NOS3—systemic scleroderma	0.00305	0.153	CbGpPWpGaD
Mefloquine—HBA1—digestive system—systemic scleroderma	0.00287	0.0333	CbGeAlD
Mefloquine—HBA2—digestive system—systemic scleroderma	0.00263	0.0306	CbGeAlD
Mefloquine—HBA1—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.0025	0.125	CbGpPWpGaD
Mefloquine—HBA1—lung—systemic scleroderma	0.0024	0.0278	CbGeAlD
Mefloquine—HBA2—lung—systemic scleroderma	0.0022	0.0256	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—CSF1—systemic scleroderma	0.00187	0.0937	CbGpPWpGaD
Mefloquine—ADORA1—tendon—systemic scleroderma	0.00113	0.0131	CbGeAlD
Mefloquine—ACHE—tendon—systemic scleroderma	0.00112	0.013	CbGeAlD
Mefloquine—CYP19A1—connective tissue—systemic scleroderma	0.00111	0.0129	CbGeAlD
Mefloquine—ADORA1—lung—systemic scleroderma	0.000989	0.0115	CbGeAlD
Mefloquine—HBA1—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000778	0.0389	CbGpPWpGaD
Mefloquine—ABCB1—blood vessel—systemic scleroderma	0.000744	0.00865	CbGeAlD
Mefloquine—BCHE—smooth muscle tissue—systemic scleroderma	0.000732	0.00851	CbGeAlD
Mefloquine—BCHE—skin of body—systemic scleroderma	0.000723	0.0084	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—CCL2—systemic scleroderma	0.000633	0.0317	CbGpPWpGaD
Mefloquine—HBA1—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00059	0.0295	CbGpPWpGaD
Mefloquine—BCHE—digestive system—systemic scleroderma	0.000578	0.00672	CbGeAlD
Mefloquine—HBA1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000503	0.0252	CbGpPWpGaD
Mefloquine—BCHE—lung—systemic scleroderma	0.000483	0.00561	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—IL1B—systemic scleroderma	0.00048	0.024	CbGpPWpGaD
Mefloquine—CYP3A4—digestive system—systemic scleroderma	0.000389	0.00452	CbGeAlD
Mefloquine—CYP2D6—digestive system—systemic scleroderma	0.000383	0.00445	CbGeAlD
Mefloquine—HBA1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000381	0.0191	CbGpPWpGaD
Mefloquine—ACHE—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000359	0.018	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—TOP1—systemic scleroderma	0.000351	0.0176	CbGpPWpGaD
Mefloquine—ABCB1—digestive system—systemic scleroderma	0.000276	0.0032	CbGeAlD
Mefloquine—ADORA2A—Circadian rythm related genes—TOP1—systemic scleroderma	0.000271	0.0136	CbGpPWpGaD
Mefloquine—ABCB1—lung—systemic scleroderma	0.00023	0.00267	CbGeAlD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000226	0.0113	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000223	0.0112	CbGpPWpGaD
Mefloquine—ADORA2A—Monoamine Transport—IL1B—systemic scleroderma	0.000215	0.0108	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—ACE—systemic scleroderma	0.000199	0.00995	CbGpPWpGaD
Mefloquine—Oedema—Lisinopril—systemic scleroderma	0.000198	0.00114	CcSEcCtD
Mefloquine—Pruritus—Captopril—systemic scleroderma	0.000197	0.00114	CcSEcCtD
Mefloquine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000197	0.00113	CcSEcCtD
Mefloquine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000197	0.00113	CcSEcCtD
Mefloquine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000196	0.00113	CcSEcCtD
Mefloquine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000195	0.00112	CcSEcCtD
Mefloquine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00112	CcSEcCtD
Mefloquine—Shock—Lisinopril—systemic scleroderma	0.000194	0.00112	CcSEcCtD
Mefloquine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000193	0.00111	CcSEcCtD
Mefloquine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000193	0.00111	CcSEcCtD
Mefloquine—Tachycardia—Lisinopril—systemic scleroderma	0.000193	0.00111	CcSEcCtD
Mefloquine—Abdominal pain—Azathioprine—systemic scleroderma	0.000192	0.00111	CcSEcCtD
Mefloquine—Body temperature increased—Azathioprine—systemic scleroderma	0.000192	0.00111	CcSEcCtD
Mefloquine—Skin disorder—Lisinopril—systemic scleroderma	0.000192	0.0011	CcSEcCtD
Mefloquine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000191	0.0011	CcSEcCtD
Mefloquine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000191	0.0011	CcSEcCtD
Mefloquine—Diarrhoea—Captopril—systemic scleroderma	0.000191	0.0011	CcSEcCtD
Mefloquine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000191	0.0011	CcSEcCtD
Mefloquine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000191	0.0011	CcSEcCtD
Mefloquine—Irritability—Methotrexate—systemic scleroderma	0.00019	0.0011	CcSEcCtD
Mefloquine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00109	CcSEcCtD
Mefloquine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00109	CcSEcCtD
Mefloquine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Mefloquine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Mefloquine—Mood swings—Methotrexate—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Mefloquine—Nausea—Mometasone—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Mefloquine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000188	0.00108	CcSEcCtD
Mefloquine—Ataxia—Methotrexate—systemic scleroderma	0.000188	0.00108	CcSEcCtD
Mefloquine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000187	0.00108	CcSEcCtD
Mefloquine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000186	0.00107	CcSEcCtD
Mefloquine—Hypotension—Lisinopril—systemic scleroderma	0.000185	0.00106	CcSEcCtD
Mefloquine—Dizziness—Captopril—systemic scleroderma	0.000184	0.00106	CcSEcCtD
Mefloquine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000184	0.00106	CcSEcCtD
Mefloquine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000183	0.00105	CcSEcCtD
Mefloquine—Urticaria—Leflunomide—systemic scleroderma	0.000183	0.00105	CcSEcCtD
Mefloquine—Abdominal pain—Leflunomide—systemic scleroderma	0.000182	0.00105	CcSEcCtD
Mefloquine—Body temperature increased—Leflunomide—systemic scleroderma	0.000182	0.00105	CcSEcCtD
Mefloquine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000181	0.00104	CcSEcCtD
Mefloquine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00104	CcSEcCtD
Mefloquine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00104	CcSEcCtD
Mefloquine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00104	CcSEcCtD
Mefloquine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00018	0.00104	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00018	0.00104	CcSEcCtD
Mefloquine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00018	0.00104	CcSEcCtD
Mefloquine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000179	0.00103	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000179	0.00103	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000179	0.00103	CcSEcCtD
Mefloquine—HBA2—Metabolism—HSPG2—systemic scleroderma	0.000179	0.00897	CbGpPWpGaD
Mefloquine—Insomnia—Lisinopril—systemic scleroderma	0.000179	0.00103	CcSEcCtD
Mefloquine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00103	CcSEcCtD
Mefloquine—BCHE—Peptide hormone metabolism—ACE—systemic scleroderma	0.000177	0.00888	CbGpPWpGaD
Mefloquine—Paraesthesia—Lisinopril—systemic scleroderma	0.000177	0.00102	CcSEcCtD
Mefloquine—Vomiting—Captopril—systemic scleroderma	0.000177	0.00102	CcSEcCtD
Mefloquine—Dyspnoea—Lisinopril—systemic scleroderma	0.000176	0.00101	CcSEcCtD
Mefloquine—Rash—Captopril—systemic scleroderma	0.000176	0.00101	CcSEcCtD
Mefloquine—Dermatitis—Captopril—systemic scleroderma	0.000176	0.00101	CcSEcCtD
Mefloquine—Somnolence—Lisinopril—systemic scleroderma	0.000176	0.00101	CcSEcCtD
Mefloquine—Headache—Captopril—systemic scleroderma	0.000175	0.00101	CcSEcCtD
Mefloquine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000175	0.001	CcSEcCtD
Mefloquine—Dyspepsia—Lisinopril—systemic scleroderma	0.000174	0.001	CcSEcCtD
Mefloquine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000173	0.000998	CcSEcCtD
Mefloquine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000173	0.000998	CcSEcCtD
Mefloquine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000996	CcSEcCtD
Mefloquine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000996	CcSEcCtD
Mefloquine—ACHE—Monoamine Transport—IL1B—systemic scleroderma	0.000172	0.00861	CbGpPWpGaD
Mefloquine—Decreased appetite—Lisinopril—systemic scleroderma	0.000172	0.000989	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000171	0.000982	CcSEcCtD
Mefloquine—Fatigue—Lisinopril—systemic scleroderma	0.00017	0.00098	CcSEcCtD
Mefloquine—Shock—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00098	CcSEcCtD
Mefloquine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00017	0.000977	CcSEcCtD
Mefloquine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000976	CcSEcCtD
Mefloquine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000169	0.000975	CcSEcCtD
Mefloquine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000972	CcSEcCtD
Mefloquine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000968	CcSEcCtD
Mefloquine—Bradycardia—Prednisone—systemic scleroderma	0.000168	0.000968	CcSEcCtD
Mefloquine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000963	CcSEcCtD
Mefloquine—Diarrhoea—Azathioprine—systemic scleroderma	0.000167	0.000959	CcSEcCtD
Mefloquine—Nausea—Captopril—systemic scleroderma	0.000166	0.000954	CcSEcCtD
Mefloquine—Asthenia—Leflunomide—systemic scleroderma	0.000165	0.00095	CcSEcCtD
Mefloquine—Hallucination—Prednisone—systemic scleroderma	0.000164	0.000946	CcSEcCtD
Mefloquine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000163	0.000937	CcSEcCtD
Mefloquine—Pruritus—Leflunomide—systemic scleroderma	0.000163	0.000936	CcSEcCtD
Mefloquine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000162	0.000934	CcSEcCtD
Mefloquine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000931	CcSEcCtD
Mefloquine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000162	0.00093	CcSEcCtD
Mefloquine—Dizziness—Azathioprine—systemic scleroderma	0.000161	0.000927	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000908	CcSEcCtD
Mefloquine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000157	0.000906	CcSEcCtD
Mefloquine—Diarrhoea—Leflunomide—systemic scleroderma	0.000157	0.000906	CcSEcCtD
Mefloquine—Urticaria—Lisinopril—systemic scleroderma	0.000157	0.000903	CcSEcCtD
Mefloquine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000901	CcSEcCtD
Mefloquine—Body temperature increased—Lisinopril—systemic scleroderma	0.000156	0.000899	CcSEcCtD
Mefloquine—Abdominal pain—Lisinopril—systemic scleroderma	0.000156	0.000899	CcSEcCtD
Mefloquine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000895	CcSEcCtD
Mefloquine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000155	0.000893	CcSEcCtD
Mefloquine—Vomiting—Azathioprine—systemic scleroderma	0.000155	0.000891	CcSEcCtD
Mefloquine—Pneumonia—Methotrexate—systemic scleroderma	0.000155	0.00089	CcSEcCtD
Mefloquine—Eye disorder—Prednisone—systemic scleroderma	0.000154	0.000888	CcSEcCtD
Mefloquine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000888	CcSEcCtD
Mefloquine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000886	CcSEcCtD
Mefloquine—Rash—Azathioprine—systemic scleroderma	0.000154	0.000884	CcSEcCtD
Mefloquine—Dermatitis—Azathioprine—systemic scleroderma	0.000153	0.000883	CcSEcCtD
Mefloquine—Flushing—Prednisone—systemic scleroderma	0.000153	0.000882	CcSEcCtD
Mefloquine—Headache—Azathioprine—systemic scleroderma	0.000153	0.000878	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000152	0.000877	CcSEcCtD
Mefloquine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000877	CcSEcCtD
Mefloquine—Dizziness—Leflunomide—systemic scleroderma	0.000152	0.000875	CcSEcCtD
Mefloquine—Renal failure—Methotrexate—systemic scleroderma	0.000151	0.00087	CcSEcCtD
Mefloquine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000866	CcSEcCtD
Mefloquine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00015	0.000864	CcSEcCtD
Mefloquine—Angiopathy—Prednisone—systemic scleroderma	0.00015	0.000862	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000149	0.00086	CcSEcCtD
Mefloquine—Sweating—Methotrexate—systemic scleroderma	0.000147	0.000848	CcSEcCtD
Mefloquine—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000147	0.00737	CbGpPWpGaD
Mefloquine—Vomiting—Leflunomide—systemic scleroderma	0.000146	0.000841	CcSEcCtD
Mefloquine—Alopecia—Prednisone—systemic scleroderma	0.000146	0.00084	CcSEcCtD
Mefloquine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000146	0.000838	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000145	0.000837	CcSEcCtD
Mefloquine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000145	0.000835	CcSEcCtD
Mefloquine—Rash—Leflunomide—systemic scleroderma	0.000145	0.000834	CcSEcCtD
Mefloquine—Dermatitis—Leflunomide—systemic scleroderma	0.000145	0.000834	CcSEcCtD
Mefloquine—Mental disorder—Prednisone—systemic scleroderma	0.000145	0.000833	CcSEcCtD
Mefloquine—Nausea—Azathioprine—systemic scleroderma	0.000145	0.000832	CcSEcCtD
Mefloquine—Headache—Leflunomide—systemic scleroderma	0.000144	0.000829	CcSEcCtD
Mefloquine—Erythema—Prednisone—systemic scleroderma	0.000144	0.000828	CcSEcCtD
Mefloquine—Malnutrition—Prednisone—systemic scleroderma	0.000144	0.000828	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000143	0.000826	CcSEcCtD
Mefloquine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000821	CcSEcCtD
Mefloquine—Asthenia—Lisinopril—systemic scleroderma	0.000142	0.000816	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000815	CcSEcCtD
Mefloquine—Pruritus—Lisinopril—systemic scleroderma	0.00014	0.000805	CcSEcCtD
Mefloquine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000139	0.000803	CcSEcCtD
Mefloquine—Rash—Mycophenolic acid—systemic scleroderma	0.000138	0.000796	CcSEcCtD
Mefloquine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000138	0.000795	CcSEcCtD
Mefloquine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000792	CcSEcCtD
Mefloquine—Headache—Mycophenolic acid—systemic scleroderma	0.000137	0.000791	CcSEcCtD
Mefloquine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000788	CcSEcCtD
Mefloquine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000788	CcSEcCtD
Mefloquine—Nausea—Leflunomide—systemic scleroderma	0.000137	0.000786	CcSEcCtD
Mefloquine—HBA1—Metabolism—HSPG2—systemic scleroderma	0.000136	0.0068	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—CTGF—systemic scleroderma	0.000136	0.0068	CbGpPWpGaD
Mefloquine—Vision blurred—Prednisone—systemic scleroderma	0.000135	0.00078	CcSEcCtD
Mefloquine—Diarrhoea—Lisinopril—systemic scleroderma	0.000135	0.000778	CcSEcCtD
Mefloquine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000133	0.000768	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—systemic scleroderma	0.000133	0.000766	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000132	0.00662	CbGpPWpGaD
Mefloquine—Agitation—Prednisone—systemic scleroderma	0.000132	0.00076	CcSEcCtD
Mefloquine—Dizziness—Lisinopril—systemic scleroderma	0.000131	0.000752	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—systemic scleroderma	0.000131	0.000751	CcSEcCtD
Mefloquine—Nausea—Mycophenolic acid—systemic scleroderma	0.00013	0.00075	CcSEcCtD
Mefloquine—Malaise—Prednisone—systemic scleroderma	0.00013	0.000746	CcSEcCtD
Mefloquine—Vertigo—Prednisone—systemic scleroderma	0.000129	0.000743	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—systemic scleroderma	0.000129	0.000742	CcSEcCtD
Mefloquine—Syncope—Prednisone—systemic scleroderma	0.000129	0.000742	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—systemic scleroderma	0.000129	0.000741	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000128	0.000737	CcSEcCtD
Mefloquine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000734	CcSEcCtD
Mefloquine—Loss of consciousness—Prednisone—systemic scleroderma	0.000126	0.000727	CcSEcCtD
Mefloquine—Vomiting—Lisinopril—systemic scleroderma	0.000126	0.000723	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—systemic scleroderma	0.000125	0.000721	CcSEcCtD
Mefloquine—Rash—Lisinopril—systemic scleroderma	0.000125	0.000717	CcSEcCtD
Mefloquine—Convulsion—Prednisone—systemic scleroderma	0.000125	0.000717	CcSEcCtD
Mefloquine—Dermatitis—Lisinopril—systemic scleroderma	0.000124	0.000716	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000124	0.000716	CcSEcCtD
Mefloquine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000715	CcSEcCtD
Mefloquine—Hypertension—Prednisone—systemic scleroderma	0.000124	0.000714	CcSEcCtD
Mefloquine—Chills—Methotrexate—systemic scleroderma	0.000124	0.000713	CcSEcCtD
Mefloquine—Headache—Lisinopril—systemic scleroderma	0.000124	0.000712	CcSEcCtD
Mefloquine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000705	CcSEcCtD
Mefloquine—Arthralgia—Prednisone—systemic scleroderma	0.000122	0.000705	CcSEcCtD
Mefloquine—Myalgia—Prednisone—systemic scleroderma	0.000122	0.000705	CcSEcCtD
Mefloquine—Anxiety—Prednisone—systemic scleroderma	0.000122	0.000702	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—systemic scleroderma	0.000122	0.000702	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000122	0.0007	CcSEcCtD
Mefloquine—Discomfort—Prednisone—systemic scleroderma	0.000121	0.000696	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—systemic scleroderma	0.000121	0.000696	CcSEcCtD
Mefloquine—Erythema—Methotrexate—systemic scleroderma	0.00012	0.000692	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—systemic scleroderma	0.00012	0.000692	CcSEcCtD
Mefloquine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000682	CcSEcCtD
Mefloquine—Nausea—Lisinopril—systemic scleroderma	0.000117	0.000675	CcSEcCtD
Mefloquine—Oedema—Prednisone—systemic scleroderma	0.000117	0.000675	CcSEcCtD
Mefloquine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000117	0.000675	CcSEcCtD
Mefloquine—Shock—Prednisone—systemic scleroderma	0.000115	0.000664	CcSEcCtD
Mefloquine—Nervous system disorder—Prednisone—systemic scleroderma	0.000115	0.000662	CcSEcCtD
Mefloquine—Tachycardia—Prednisone—systemic scleroderma	0.000115	0.000659	CcSEcCtD
Mefloquine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000659	CcSEcCtD
Mefloquine—Skin disorder—Prednisone—systemic scleroderma	0.000114	0.000656	CcSEcCtD
Mefloquine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000113	0.000653	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—systemic scleroderma	0.000113	0.000652	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000111	0.000642	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000111	0.00554	CbGpPWpGaD
Mefloquine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000634	CcSEcCtD
Mefloquine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000628	CcSEcCtD
Mefloquine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000628	CcSEcCtD
Mefloquine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000624	CcSEcCtD
Mefloquine—Malaise—Methotrexate—systemic scleroderma	0.000108	0.000624	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—systemic scleroderma	0.000108	0.000621	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—systemic scleroderma	0.000108	0.000619	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000107	0.000615	CcSEcCtD
Mefloquine—Insomnia—Prednisone—systemic scleroderma	0.000106	0.000611	CcSEcCtD
Mefloquine—Paraesthesia—Prednisone—systemic scleroderma	0.000105	0.000606	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—systemic scleroderma	0.000104	0.000599	CcSEcCtD
Mefloquine—Dyspepsia—Prednisone—systemic scleroderma	0.000103	0.000595	CcSEcCtD
Mefloquine—HBA1—Metabolism—CTGF—systemic scleroderma	0.000103	0.00515	CbGpPWpGaD
Mefloquine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000592	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—systemic scleroderma	0.000102	0.000589	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—systemic scleroderma	0.000102	0.000589	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—systemic scleroderma	0.000102	0.000589	CcSEcCtD
Mefloquine—Decreased appetite—Prednisone—systemic scleroderma	0.000102	0.000587	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000102	0.000585	CcSEcCtD
Mefloquine—Fatigue—Prednisone—systemic scleroderma	0.000101	0.000582	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—systemic scleroderma	0.000101	0.000582	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—systemic scleroderma	9.89e-05	0.000569	CcSEcCtD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	9.83e-05	0.00492	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Methotrexate—systemic scleroderma	9.81e-05	0.000564	CcSEcCtD
Mefloquine—Feeling abnormal—Prednisone—systemic scleroderma	9.67e-05	0.000557	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—systemic scleroderma	9.62e-05	0.000554	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—systemic scleroderma	9.6e-05	0.000553	CcSEcCtD
Mefloquine—Gastrointestinal pain—Prednisone—systemic scleroderma	9.59e-05	0.000552	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—systemic scleroderma	9.53e-05	0.000548	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—systemic scleroderma	9.48e-05	0.000546	CcSEcCtD
Mefloquine—Urticaria—Prednisone—systemic scleroderma	9.32e-05	0.000537	CcSEcCtD
Mefloquine—Abdominal pain—Prednisone—systemic scleroderma	9.28e-05	0.000534	CcSEcCtD
Mefloquine—Body temperature increased—Prednisone—systemic scleroderma	9.28e-05	0.000534	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—systemic scleroderma	9.16e-05	0.000527	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	8.93e-05	0.000514	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	8.91e-05	0.00446	CbGpPWpGaD
Mefloquine—Insomnia—Methotrexate—systemic scleroderma	8.87e-05	0.000511	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—systemic scleroderma	8.81e-05	0.000507	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—systemic scleroderma	8.74e-05	0.000503	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—systemic scleroderma	8.72e-05	0.000502	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	8.68e-05	0.00434	CbGpPWpGaD
Mefloquine—Hypersensitivity—Prednisone—systemic scleroderma	8.64e-05	0.000498	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—systemic scleroderma	8.63e-05	0.000497	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—systemic scleroderma	8.52e-05	0.000491	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.47e-05	0.000487	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—systemic scleroderma	8.45e-05	0.000487	CcSEcCtD
Mefloquine—Asthenia—Prednisone—systemic scleroderma	8.42e-05	0.000485	CcSEcCtD
Mefloquine—Pruritus—Prednisone—systemic scleroderma	8.3e-05	0.000478	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	8.09e-05	0.00405	CbGpPWpGaD
Mefloquine—Feeling abnormal—Methotrexate—systemic scleroderma	8.08e-05	0.000465	CcSEcCtD
Mefloquine—Diarrhoea—Prednisone—systemic scleroderma	8.03e-05	0.000462	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.02e-05	0.000462	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—systemic scleroderma	7.79e-05	0.000448	CcSEcCtD
Mefloquine—Dizziness—Prednisone—systemic scleroderma	7.76e-05	0.000447	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—systemic scleroderma	7.75e-05	0.000446	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—systemic scleroderma	7.75e-05	0.000446	CcSEcCtD
Mefloquine—Vomiting—Prednisone—systemic scleroderma	7.46e-05	0.000429	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	7.41e-05	0.00371	CbGpPWpGaD
Mefloquine—Rash—Prednisone—systemic scleroderma	7.4e-05	0.000426	CcSEcCtD
Mefloquine—Dermatitis—Prednisone—systemic scleroderma	7.39e-05	0.000425	CcSEcCtD
Mefloquine—Headache—Prednisone—systemic scleroderma	7.35e-05	0.000423	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	7.34e-05	0.00367	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—RHOB—systemic scleroderma	7.32e-05	0.00366	CbGpPWpGaD
Mefloquine—Hypersensitivity—Methotrexate—systemic scleroderma	7.22e-05	0.000416	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—systemic scleroderma	7.04e-05	0.000405	CcSEcCtD
Mefloquine—Nausea—Prednisone—systemic scleroderma	6.97e-05	0.000401	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	6.97e-05	0.00349	CbGpPWpGaD
Mefloquine—Pruritus—Methotrexate—systemic scleroderma	6.94e-05	0.000399	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	6.93e-05	0.00347	CbGpPWpGaD
Mefloquine—Diarrhoea—Methotrexate—systemic scleroderma	6.71e-05	0.000386	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	6.7e-05	0.00335	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RHOB—systemic scleroderma	6.64e-05	0.00332	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—EDN1—systemic scleroderma	6.61e-05	0.00331	CbGpPWpGaD
Mefloquine—Dizziness—Methotrexate—systemic scleroderma	6.48e-05	0.000373	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—systemic scleroderma	6.23e-05	0.000359	CcSEcCtD
Mefloquine—Rash—Methotrexate—systemic scleroderma	6.18e-05	0.000356	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—systemic scleroderma	6.18e-05	0.000356	CcSEcCtD
Mefloquine—Headache—Methotrexate—systemic scleroderma	6.14e-05	0.000354	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.13e-05	0.00307	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	5.93e-05	0.00297	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—NOS3—systemic scleroderma	5.91e-05	0.00296	CbGpPWpGaD
Mefloquine—Nausea—Methotrexate—systemic scleroderma	5.82e-05	0.000335	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—RHOB—systemic scleroderma	5.65e-05	0.00283	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.63e-05	0.00282	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.47e-05	0.00274	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RHOB—systemic scleroderma	5.13e-05	0.00257	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—EDN1—systemic scleroderma	5.1e-05	0.00255	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SMAD7—systemic scleroderma	5.07e-05	0.00254	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.65e-05	0.00232	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.58e-05	0.00229	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CCL2—systemic scleroderma	4.52e-05	0.00226	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—NOS3—systemic scleroderma	4.48e-05	0.00224	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.27e-05	0.00214	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.14e-05	0.00207	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RHOB—systemic scleroderma	3.93e-05	0.00196	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SMAD7—systemic scleroderma	3.92e-05	0.00196	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—ACE—systemic scleroderma	3.75e-05	0.00188	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—EDN1—systemic scleroderma	3.74e-05	0.00187	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HSPG2—systemic scleroderma	3.7e-05	0.00185	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	3.63e-05	0.00182	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CSK—systemic scleroderma	3.58e-05	0.00179	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CCL2—systemic scleroderma	3.49e-05	0.00175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EDN1—systemic scleroderma	3.39e-05	0.0017	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—ACE—systemic scleroderma	3.35e-05	0.00168	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.2e-05	0.0016	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RHOB—systemic scleroderma	3.03e-05	0.00152	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—EDN1—systemic scleroderma	2.88e-05	0.00144	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HSPG2—systemic scleroderma	2.86e-05	0.00143	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	2.82e-05	0.00141	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CSK—systemic scleroderma	2.76e-05	0.00138	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—HSPG2—systemic scleroderma	2.73e-05	0.00137	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EDN1—systemic scleroderma	2.62e-05	0.00131	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—HSPG2—systemic scleroderma	2.51e-05	0.00126	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—HSPG2—systemic scleroderma	2.44e-05	0.00122	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—MMP1—systemic scleroderma	2.41e-05	0.00121	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CCL2—systemic scleroderma	2.32e-05	0.00116	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—MMP1—systemic scleroderma	2.15e-05	0.00108	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CTGF—systemic scleroderma	2.07e-05	0.00104	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EDN1—systemic scleroderma	2e-05	0.001	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CCL2—systemic scleroderma	1.96e-05	0.000981	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CTGF—systemic scleroderma	1.9e-05	0.000951	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—MMP2—systemic scleroderma	1.87e-05	0.000933	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CTGF—systemic scleroderma	1.85e-05	0.000924	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CCL2—systemic scleroderma	1.79e-05	0.000896	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CCL2—systemic scleroderma	1.75e-05	0.000875	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—MMP2—systemic scleroderma	1.66e-05	0.000833	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EDN1—systemic scleroderma	1.55e-05	0.000774	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.39e-05	0.000697	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCL2—systemic scleroderma	1.37e-05	0.000686	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NOS3—systemic scleroderma	1.22e-05	0.000611	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.19e-05	0.000595	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.12e-05	0.00056	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCL2—systemic scleroderma	1.06e-05	0.000529	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—systemic scleroderma	9.8e-06	0.00049	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOS3—systemic scleroderma	9.43e-06	0.000472	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CTGF—systemic scleroderma	9.01e-06	0.000451	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NOS3—systemic scleroderma	9.01e-06	0.000451	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CTGF—systemic scleroderma	8.49e-06	0.000425	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NOS3—systemic scleroderma	8.28e-06	0.000414	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFB1—systemic scleroderma	8.07e-06	0.000404	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NOS3—systemic scleroderma	8.03e-06	0.000402	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—systemic scleroderma	7.56e-06	0.000379	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.32e-06	0.000366	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFB1—systemic scleroderma	6.23e-06	0.000312	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CTGF—systemic scleroderma	5.55e-06	0.000278	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NOS3—systemic scleroderma	3.92e-06	0.000196	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NOS3—systemic scleroderma	3.69e-06	0.000185	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.42e-06	0.000121	CbGpPWpGaD
